*February 2021* In EGFR-mutant non–small cell lung cancer (NSCLC) and brain metastases, oral osimertinib (Tagrisso) achieved rapid, high, and uniform
*February 2021* Highlights from Dr. Collin Blakely's presentation: EGFR TKI Combination Therapies: C797S, MEK, AURORA Kinase at the 2021 Targeted
*January 2021* The utility of EGFR TKIs in select subgroups of patients with EGFR-mutant metastatic non–small cell lung cancer (NSCLC), as
*January 2021* Poziotinib, mobocertinib (TAK-788), and fam-trastuzumab deruxtecan-nxki (Enhertu) are among some of the agents that have positioned HER2 as a must-test
*January 2021* The treatment paradigms of early-stage and metastatic lung cancer have expanded significantly in recent years with the addition
*January 2021* Atezolizumab (Tecentriq), durvalumab (Imfinzi), pembrolizumab (Keytruda), and nivolumab (Opdivo) have demonstrated improved survival in combination with etoposide and
*January 2021* The combination of osimertinib (Tagrisso) plus bevacizumab (Avastin) failed to result in a statistically significant improvement in progression-free
*January 2021* Osimertinib (Tagrisso) has a strong foothold as first-line therapy for patients with advanced EGFR-mutated non-small cell lung cancer
*January 2021* The ATOMIC consortium is a group of thoracic oncologists from North America. They received funding from AstraZeneca to
*January 2021* Patritumab deruxtecan demonstrated early and clinically meaningful activity in pretreated patients with metastatic or unresectable EGFR-mutant non–small cell
